Today, only the two HDAC inhibitors (HDACi) suberoylanilide hydroxamic acid (SAHA, VorinostatTM) and the microbial metabolite FK228 (Romidepsin, IstodaxTM) have been approved by the FDA for the treatment of cancer [32], [33]. This evidence concerns the gene HDAC9 and cancer.